RESUMEN
Here, an optical sensor with specific binding sites for sensitive and selective detection of thioridazine hydrochloride (THZ) was prepared. The optosensor was developed based on ZnO quantum dots (QDs) coated with molecularly imprinted polymers (MIPs). Initially, ZnO quantum dots (QDs) were synthesized by precipitation from Zn(CH3COO)2 and NaOH then, reverse microemulsion method was applied for fixing the MIPs layer on the surface of QDs. It was perceived that the fluorescence intensity of the QDs-MIPs quenched with increasing THZ concentration. Several parameters affect the optical sensor response were studied and optimized. Under the optimal conditions, THZ could be determined with a linear dynamic range of 4-120â¯nmolâ¯L-1 and with a low detection limit of 0.43â¯nmolâ¯L-1. The relative standard deviations for 25 and 60â¯nmolâ¯L-1 of THZ were obtained as 4.9% and 3.1%, respectively (three times measurement). High selectivity, simplicity, and cost-efficient for THZ measurement are the most important advantages of the fluorimetric sensor.
Asunto(s)
Impresión Molecular/métodos , Puntos Cuánticos/química , Espectrometría de Fluorescencia/métodos , Tioridazina/sangre , Óxido de Zinc/química , Humanos , Límite de Detección , Modelos Lineales , Nanocompuestos , Reproducibilidad de los Resultados , Tioridazina/químicaRESUMEN
Simple and rapid determinations of some psychotropic drugs in some pharmaceutical wastewater and human plasma samples were successfully accomplished via the tandem dispersive liquid-liquid microextraction combined with high performance liquid chromatography-ultraviolet detection (TDLLME-HPLC-UV). TDLLME of the three psychotropic drugs clozapine, chlorpromazine, and thioridazine was easily performed through two consecutive dispersive liquid-liquid microextractions. By performing this convenient method, proper sample preconcentrations and clean-ups were achieved in just about 7min. In order to achieve the best extraction efficiency, the effective parameters involved were optimized. The optimal experimental conditions consisted of 100µL of CCl4 (as the extraction organic solvent), and the pH values of 13 and 2 for the donor and acceptor phases, respectively. Under these optimum experimental conditions, the proposed TDLLME-HPLC-UV technique provided a good linearity in the range of 5-3000ngmL-1 for the three psychotropic drugs with the correlation of determinations (R2s) higher than 0.996. The limits of quantification (LOQs) and limits of detection (LODs) obtained were 5.0ngmL-1 and 1.0-1.5ngmL-1, respectively. Also the proper enrichment factors (EFs) of 96, 99, and 88 for clozapine, chlorpromazine, and thioridazine, respectively, and good extraction repeatabilities (relative standard deviations below 9.3%, n=5) were obtained.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Microextracción en Fase Líquida/métodos , Psicotrópicos/análisis , Psicotrópicos/sangre , Aguas Residuales/análisis , Clorpromazina/análisis , Clorpromazina/sangre , Clorpromazina/aislamiento & purificación , Cromatografía Líquida de Alta Presión/economía , Clozapina/análisis , Clozapina/sangre , Clozapina/aislamiento & purificación , Humanos , Límite de Detección , Microextracción en Fase Líquida/economía , Psicotrópicos/aislamiento & purificación , Tioridazina/análisis , Tioridazina/sangre , Tioridazina/aislamiento & purificación , Factores de TiempoRESUMEN
OBJECTIVE: The anticholinergic activity (AA) assay is a common method to determine a patient's anticholinergic load. Several limitations, however, are expected when applying the AA assay to patients or using drug scales to estimate anticholinergic burden based on AA levels. This study aims to demonstrate common pitfalls in an experimental setting and outline their clinical consequences. METHODS: The AA was analyzed for five drugs with reported interaction with muscarinic receptors. Concentration-response curves were constructed for furosemide (weak anticholinergic), diphenhydramine (moderate anticholinergic), the strong anticholinergic amitriptyline and its metabolite nortriptyline, and the cholinergic pilocarpine. The Combination Index (CI) was used to assess the interaction of three drug combinations with amitriptyline. RESULTS: All compounds displaced the radioactive tracer from its receptor binding site in a concentration-dependent manner, and full displacement was reached for all compounds except furosemide (Emax 16%). The CI indicated that amitriptyline and thioridazine have antagonistic effects (CI = 1.46) at low and synergistic effects (CI = 0.88) at higher concentrations (p < 0.0001), whereas synergistic effects (CI = 0.47-0.48) were observed for amitriptyline in any concentration combined with pilocarpine (p < 0.001). CONCLUSION: When the patient's anticholinergic load is estimated using AA levels, the actual exposure, combination of anticholinergic drugs, their active metabolites, and also drugs with an opposite pharmacologic action will contribute to AA levels, whereas weak anticholinergic drugs in therapeutic concentrations are rather negligible.
Asunto(s)
Antagonistas Colinérgicos/efectos adversos , Amitriptilina/efectos adversos , Amitriptilina/sangre , Amitriptilina/uso terapéutico , Antagonistas Colinérgicos/sangre , Antagonistas Colinérgicos/uso terapéutico , Disfunción Cognitiva/inducido químicamente , Disfunción Cognitiva/prevención & control , Difenhidramina/sangre , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Furosemida/efectos adversos , Furosemida/sangre , Furosemida/uso terapéutico , Humanos , Nortriptilina/sangre , Pilocarpina/sangre , Ensayo de Unión Radioligante , Tioridazina/sangreRESUMEN
CONTEXT: Use of second generation antipsychotics in England and Wales has increased in recent years whilst prescription of first generation antipsychotics has decreased. METHODS: To evaluate the impact of this change and of the withdrawal of thioridazine in 2000 on antipsychotic-related fatal poisoning, we reviewed all such deaths in England and Wales 1993-2013 recorded on the Office for National Statistics drug poisoning deaths database. We also reviewed antipsychotic prescribing in the community, England and Wales, 2001-2013. Use of routine mortality data: When an antipsychotic was recorded with other drug(s), the death certificate does not normally say if the antipsychotic caused the death rather than the other substance(s). A second consideration concerns intent. A record of "undetermined intent" is likely to have been intentional self-poisoning, the evidence being insufficient to be certain that the individual intended to kill. A record of drug abuse/dependence, on the other hand, is likely to have been associated with an unintentional death. Accuracy of the diagnosis of poisoning: When investigating a death in someone prescribed antipsychotics, toxicological analysis of biological samples collected post-mortem is usually performed. However, prolonged attempts at resuscitation, or diffusion from tissues into blood as autolysis proceeds, may serve to alter the composition of blood sampled after death from that circulating at death. With chlorpromazine and with olanzapine a further factor is that these compounds are notoriously unstable in post-mortem blood. Deaths from antipsychotics: There were 1544 antipsychotic-related poisoning deaths. Deaths in males (N = 948) were almost twice those in females. For most antipsychotics, the proportion of deaths in which a specific antipsychotic featured either alone, or only with alcohol was 30-40%, but for clozapine (193 deaths) such mentions totalled 66%. For clozapine, the proportion of deaths attributed to either intentional self-harm, or undetermined intent was 44%, but for all other drugs except haloperidol (20 deaths) the proportion was 56% or more. The annual number of antipsychotic-related deaths increased from some 55 per year (1.0 per million population) between 1993 and 1998 to 74 (1.5 per million population) in 2000, and then after falling slightly in 2002 increased steadily to reach 109 (1.9 per million population) in 2013. Intent: The annual number of intentional and unascertained intent poisoning deaths remained relatively constant throughout the study period (1993: 35 deaths, 2013: 38 deaths) hence the increase in antipsychotic-related deaths since 2002 was almost entirely in unintentional poisoning involving second generation antipsychotics. Clozapine, olanzapine, and quetiapine were the second generation antipsychotics mentioned most frequently in unintentional poisonings (99, 136, and 99 deaths, respectively). Mentions of diamorphine/morphine and methadone (67 and 99 deaths, respectively) together with an antipsychotic were mainly (84 and 90%, respectively) in either unintentional or drug abuse-related deaths. Deaths and community prescriptions: Deaths involving antipsychotics (10 or more deaths) were in the range 11.3-17.1 deaths per million community prescriptions in England and Wales, 2001-2013. Almost all (96%) such deaths now involve second generation antipsychotics. This is keeping with the increase in annual numbers of prescriptions of these drugs overall (<1 million in 2000, 7 million in 2013), largely driven by increases in prescriptions for olanzapine and quetiapine. In contrast, deaths involving thioridazine declined markedly (from 40 in 2000 to 10 in 2003-2013) in line with the fall in prescriptions for thioridazine from 2001. CONCLUSIONS: The removal of thioridazine has had no apparent effect on the incidence of antipsychotic-related fatal poisoning in England and Wales. That such deaths have increased steadily since 2001 is in large part attributable to an increase in unintentional deaths related to (i) clozapine, and (ii) co-exposure to opioids, principally diamorphine and methadone.
Asunto(s)
Antipsicóticos/envenenamiento , Recall de Medicamento , Intoxicación/mortalidad , Tioridazina/envenenamiento , Antipsicóticos/sangre , Benzodiazepinas/sangre , Benzodiazepinas/envenenamiento , Clorpromazina/sangre , Clorpromazina/envenenamiento , Clozapina/sangre , Clozapina/envenenamiento , Inglaterra/epidemiología , Heroína/sangre , Heroína/envenenamiento , Humanos , Metadona/sangre , Metadona/envenenamiento , Morfina/sangre , Morfina/envenenamiento , Olanzapina , Intoxicación/etiología , Fumarato de Quetiapina/sangre , Fumarato de Quetiapina/envenenamiento , Tioridazina/sangre , Gales/epidemiologíaRESUMEN
In this approach, synthesis of nickel (II) incorporated aluminophosphate (NiAlPO-5) was performed by using hydrothermal method. The diffuse reflectance spectroscopy (DRS), scanning electron microscopy (SEM), and Fourier transform infrared spectroscopy (FTIR) techniques were applied in order to characterize synthesized compounds. The NiAlPO-5 was used as a modifier in carbon paste electrode for the selective determination of thioridazine which is an antidepressant drug. This research is the first example of an aluminophosphate being employed in electroanalysis. The effective catalytic role of the modified electrode toward thioridazine oxidation can be attributed to the electrocatalytic activity of nickel (II) in the aluminaphosphate matrix. In addition, NiAlPO-5 has unique properties such as the high specific surface area which increases the electron transfer of thioridazine. The effects of varying the percentage of modifier, pH and potential sweep rate on the electrode response were investigated. Differential pulse voltammetry was used for quantitative determination as a sensitive method. A dynamic linear range was obtained in the range of 1.0×10(-7)-1.0×10(-5)mol L(-1). The determination of thioridazine in real samples such as commercial tablets and human serum was demonstrated.
Asunto(s)
Compuestos de Aluminio/química , Antidepresivos/análisis , Técnicas Electroquímicas , Níquel/química , Fosfatos/química , Tioridazina/análisis , Compuestos de Aluminio/síntesis química , Antidepresivos/sangre , Carbono/química , Catálisis , Electrodos , Humanos , Concentración de Iones de Hidrógeno , Oxidación-Reducción , Fosfatos/síntesis química , Comprimidos/química , Tioridazina/sangreRESUMEN
BACKGROUND: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. METHODS: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. RESULTS: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. CONCLUSIONS: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.
Asunto(s)
Dibenzotiazepinas/administración & dosificación , Dibenzotiazepinas/sangre , Esquizofrenia/sangre , Esquizofrenia/tratamiento farmacológico , Tioridazina/administración & dosificación , Tioridazina/sangre , Adulto , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Dibenzotiazepinas/antagonistas & inhibidores , Interacciones Farmacológicas/fisiología , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fumarato de Quetiapina , Esquizofrenia/epidemiología , Taiwán/epidemiologíaRESUMEN
AIMS: The CYP2D6 -1584C>G (rs1080985) polymorphism has been identified as another major factor for CYP2D6 function that is possibly associated with ultrarapid metabolism. The mutant -1584G promoter genotype seems to be consistently related to a higher protein expression than -1584C. However, the impact this SNP in the CYP2D6 promoter region has on plasma levels of patients taking CYP2D6 substrates, such as thioridazine, has not been studied. Previously, we showed the validity of the mesoridazine:thioridazine ratio to assess CYP2D6 activity in clinical settings. Therefore, the aim of this study was to analyze the relationship between the presence of the CYP2D6 -1584C>G polymorphism and the plasma concentrations of thioridazine and its metabolites in a previously studied population of patients in order to evaluate the implications for CYP2D6 hydroxylation capacity. MATERIALS & METHODS: The CYP2D6 -1584C>G polymorphism was determined by using a PCR-RFLP method in 61 Caucasian psychiatric patients receiving thioridazine monotherapy. RESULTS: Among patients with two active CYP2D6 genes, there were significant differences in the thioridazine:mesoridazine plasma concentrations ratio (p < 0.05) among the three CYP2D6 -1584C>G genotype groups. Moreover, in this group of patients the thioridazine:mesoridazine ratio was lower (p < 0.05) in carriers of CYP2D6 -1584G allele than in patients homozygous for CYP2D6 -1584C allele. However, no differences in thioridazine or its metabolite concentrations between homozygous CYP2D6 -1584C allele carriers and carriers of the -1584G allele were found. CONCLUSION: According to the present results the concentration ratio of thioridazine to mesoridazine was related to the CYP2D6 -1584C>G polymorphism. It is likely that individuals who carry CYP2D6 -1584G versus homozygotes for the -1584C allele may present an increased CYP2D6 activity.
Asunto(s)
Antipsicóticos/sangre , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/genética , Mesoridazina/sangre , Polimorfismo de Nucleótido Simple/genética , Tioridazina/sangre , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Femenino , Tamización de Portadores Genéticos , Genotipo , Humanos , Masculino , Trastornos Mentales/sangre , Trastornos Mentales/enzimología , Persona de Mediana Edad , Mutación , Especificidad por Sustrato/genéticaRESUMEN
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study. Mean maximum increases in the QTc interval following thioridazine (37.3+/-4.1 ms, P=0.023) and mesoridazine (46.6+/-7.4 ms, P=0.021) were similar and significantly greater than following placebo (12.9+/-8.1 ms). The area under the effect-time curve over 8 h following drug administration was similar between the two drugs (129.3+/-22.1 vs 148.3+/-43.0 ms h). In conclusion, thioridazine and mesoridazine are associated with similar effects on the QTc interval.
Asunto(s)
Antipsicóticos/efectos adversos , Antagonistas de Dopamina/efectos adversos , Sistema de Conducción Cardíaco/efectos de los fármacos , Mesoridazina/efectos adversos , Tioridazina/efectos adversos , Administración Oral , Adulto , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Antipsicóticos/farmacocinética , Área Bajo la Curva , Estudios Cruzados , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/sangre , Antagonistas de Dopamina/farmacocinética , Método Doble Ciego , Electrocardiografía , Femenino , Humanos , Síndrome de QT Prolongado/inducido químicamente , Síndrome de QT Prolongado/fisiopatología , Masculino , Mesoridazina/administración & dosificación , Mesoridazina/sangre , Mesoridazina/farmacocinética , Persona de Mediana Edad , Valores de Referencia , Tioridazina/administración & dosificación , Tioridazina/sangre , Tioridazina/farmacocinéticaRESUMEN
The objective of this study was to investigate factors affecting steady-state plasma concentrations of thioridazine. A cross-sectional study of patients receiving chronic thioridazine was employed. Common allelic variants of CYP2D6 and CYP2C19, as well as thioridazine and metabolite concentrations and QTc intervals, were determined. In 97 patients, dose-corrected plasma concentrations (C/Ds) of thioridazine and metabolites were correlated with age but not sex or CYP2C19 genotype. Patients with no functional CYP2D6 alleles (n=9) had significantly higher C/D for thioridazine (P=0.017) and the ring sulfoxide metabolite and a significantly higher thioridazine/mesoridazine ratio compared with those with >/=1 functional CYP2D6 allele (n=82). Smokers had significantly lower C/D for thioridazine, mesoridazine, and sulforidazine and significantly lower thioridazine/ring sulfoxide ratios than non-smokers. QTc interval was not significantly affected by CYP2D6 or CYP2C19 genotypes. Plasma concentrations of thioridazine are influenced by age, smoking, and CYP2D6 genotype, but CYP2D6 genotype does not appear to influence on-treatment QTc interval.
Asunto(s)
Antipsicóticos/efectos adversos , Antipsicóticos/sangre , Sistema de Conducción Cardíaco/efectos de los fármacos , Síndrome de QT Prolongado/inducido químicamente , Tioridazina/efectos adversos , Tioridazina/sangre , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Alelos , Antipsicóticos/administración & dosificación , Antipsicóticos/farmacocinética , Hidrocarburo de Aril Hidroxilasas/genética , Hidrocarburo de Aril Hidroxilasas/metabolismo , Estudios Transversales , Citocromo P-450 CYP2C19 , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Antagonistas de Dopamina/efectos adversos , Antagonistas de Dopamina/sangre , Femenino , Variación Genética , Genotipo , Humanos , Modelos Lineales , Síndrome de QT Prolongado/sangre , Síndrome de QT Prolongado/fisiopatología , Masculino , Mesoridazina/efectos adversos , Mesoridazina/sangre , Persona de Mediana Edad , Oxigenasas de Función Mixta/genética , Oxigenasas de Función Mixta/metabolismo , Factores de Riesgo , Esquizofrenia/tratamiento farmacológico , Factores Sexuales , Fumar/efectos adversos , Tioridazina/administración & dosificación , Tioridazina/farmacocinética , Población Blanca/genéticaRESUMEN
Antipsychotic drugs may be associated with arrhythmia, ventricular fibrillation, or torsades de pointes, which can result in sudden death. These drugs could therefore be found in postmortem toxicological analyses of autopsy specimens following unexplained sudden death. The drug concentrations in tissues and body fluids change between the death and postmortem specimens collection because of postmortem redistribution. For this reason, it is often difficult to interpret the postmortem analysis. The aim of this study was to investigate postmortem redistribution of the two cardiotoxic antipsychotic drugs, haloperidol and thioridazine, in order to interpret the postmortem analysis. We have chosen the rat as an animal model. The rats received 1 mg/kg of haloperidol and 5 mg/kg of thioridazine by intraperitoneal injection. They were sacrificed and left at room temperature for 2, 6, 12, 24, or 48 h, at which times blood and tissue samples were taken. The drug analyses in tissues and blood were done using a liquid chromatography- tandem mass spectrometry method. Our results show that there is a redistribution of the two drugs from the lung to the cardiac blood. The concentration of the antipsychotic drugs in the lung decreased rapidly, whereas in the cardiac blood, this concentration increased within the first 2 h postmortem. By 48 h after death, the concentrations of the antipsychotic drugs were about twice as high as the initial concentrations in the cardiac blood. For the lungs, a decrease of 50% was observed between 0 and 48 h. Only myocardium and muscle concentrations did not change with the postmortem delay.
Asunto(s)
Antipsicóticos/farmacocinética , Haloperidol/farmacocinética , Cambios Post Mortem , Tioridazina/farmacocinética , Animales , Antipsicóticos/sangre , Cromatografía Liquida , Medicina Legal , Haloperidol/sangre , Masculino , Espectrometría de Masas , Modelos Animales , Ratas , Ratas Wistar , Tioridazina/sangre , Distribución TisularRESUMEN
The purpose of this study was to evaluate a telemetry system for examining QT evaluation in the conscious free-moving guinea pig using 10 reference compounds whose effects on human QT interval are well established: 8 positive references (bepridil, terfenadine, cisapride, haloperidol, pimozide, quinidine, E-4031 and thioridazine), and 2 negative references (propranolol and nifedipine). Pharmacokinetic experiments were also performed for the 8 positive references. Telemetry transmitters were implanted subcutaneously in male Hartley guinea pigs, and the RR and QT intervals were measured. All 8 positive references prolonged QTc (QTc = k x QT/RR(1/2)) 10% or more during the 60 min observation period. When the values of the QTc changes were plotted against the serum concentrations, the resulting curves exhibited an anticlockwise hysteresis loop for all 8 references. In guinea pigs treated with haloperidol, changes of the T-wave shape from positive to flat were observed. The 2 negative references did not prolong the QTc. These findings suggest that the present telemetry guinea pig model is useful for QT evaluation in the early stages of drug development, because of the small body size of guinea pigs and their action potential configuration, which is similar to that of humans.
Asunto(s)
Electrocardiografía/métodos , Síndrome de QT Prolongado/fisiopatología , Telemetría/métodos , Animales , Antiarrítmicos/administración & dosificación , Antiarrítmicos/sangre , Antiarrítmicos/farmacocinética , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Antipsicóticos/farmacocinética , Bepridil/administración & dosificación , Bepridil/sangre , Bepridil/farmacocinética , Cisaprida/administración & dosificación , Cisaprida/sangre , Cisaprida/farmacocinética , Modelos Animales de Enfermedad , Cobayas , Haloperidol/administración & dosificación , Haloperidol/sangre , Haloperidol/farmacocinética , Corazón/efectos de los fármacos , Corazón/fisiología , Corazón/fisiopatología , Humanos , Inyecciones Intravenosas , Síndrome de QT Prolongado/inducido químicamente , Síndrome de QT Prolongado/diagnóstico , Masculino , Nifedipino/administración & dosificación , Nifedipino/sangre , Nifedipino/farmacocinética , Pimozida/administración & dosificación , Pimozida/sangre , Pimozida/farmacocinética , Piperidinas/administración & dosificación , Piperidinas/sangre , Piperidinas/farmacocinética , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/farmacocinética , Quinidina/administración & dosificación , Quinidina/sangre , Quinidina/farmacocinética , Reproducibilidad de los Resultados , Terfenadina/administración & dosificación , Terfenadina/sangre , Terfenadina/farmacocinética , Tioridazina/administración & dosificación , Tioridazina/sangre , Tioridazina/farmacocinéticaRESUMEN
Thioridazine (THD) is a phenothiazine neuroleptic drug used for the treatment of psychiatric disorders. After oral administration THD is extensively biotransformed to thioridazine 2-sulfone (THD 2-SO(2)), thioridazine 5-sulfoxide (THD 5-SO) and thioridazine 2-sulfoxide (THD 2-SO). THD 2-SO and THD 5-SO have two chiral centres and therefore exist as two diastereoisomeric pairs. The degradation and epimerization of THD 2-SO in human plasma, buffer and methanolic solutions were studied using an enantioselective HPLC method. The samples were prepared by liquid-liquid extraction with diethyl ether and the chiral resolution of the enantiomers was carried out on a Chiralpak AD column using a mobile phase consisting of hexane:ethanol:2-propanol (90:7:3, v/v/v) containing 0.2% diethylamine. The method was validated and used to study the degradation and epimerization under different conditions of incubation. Our results showed that both enantiomers were stable at varying temperatures, pH and ionic strengths; however, solubility problems were observed, mainly at pH 8.5. The influence of light on stability was studied using methanolic solutions and degradation and epimerization of the THD 2-SO enantiomers were observed under UV light of 366 and 254nm, respectively.
Asunto(s)
Sulfóxidos/sangre , Sulfóxidos/química , Tioridazina/análogos & derivados , Tioridazina/sangre , Humanos , Conformación Molecular , Tioridazina/metabolismoRESUMEN
We present a method for the stereoselective analysis of thioridazine 5-sulfoxide (THD 5-SO) in human plasma based on liquid-liquid extraction with diethyl ether and chiral resolution of the stereoisomers by capillary electrophoresis using hydroxypropyl-beta-cyclodextrin and sulfated beta-cyclodextrin as chiral selectors. The method showed recovery rates of 85.5% for both THD 5-SO (slow-eluting, SE) enantiomers. The coefficients of variation observed in the precision studies, as well as the accuracy values, were below 10%. After validation, the method was used to study the stability and configurational changes of this THD metabolite. Our results showed that both enantiomers of THD 5-SO (SE) were stable under conditions of variation of temperatures (38 degrees C, 4 degrees C and -20 degrees C), pH (5.0, 7.0 and 8.5) and ionic strengths (0.2, 0.5 and 1.0 mol/L). The influence of light on the stability of the THD 5-SO (SE) stereoisomers was also studied using standard solutions prepared in methanol and an inversion in configuration was observed under UV light (254 and 366 nm).
Asunto(s)
Electroforesis Capilar/métodos , Tioridazina/análogos & derivados , Tioridazina/sangre , Tioridazina/metabolismo , Ciclodextrinas , Estabilidad de Medicamentos , Humanos , Concentración de Iones de Hidrógeno , Estructura Molecular , Concentración Osmolar , Estereoisomerismo , Temperatura , Rayos UltravioletaRESUMEN
We present two methods for the enantioselective analysis of thioridazine (THD) and thioridazine 2-sulfone (THD 2-SO(2)) in human plasma based on liquid-liquid extraction with diethyl ether and chiral resolution of the enantiomers on Chiralpak AD and Chiralcel OD-H columns, respectively. After validation, the methods were used to study the degradation and racemization of both drug and metabolite. Our results showed that both enantiomers of THD and THD 2-SO(2) were stable at varying temperatures, pH, and ionic strengths; however, solubility problems for THD and THD 2-SO(2) enantiomers were observed, mainly at pH 8.5. The influence of light on the stability of the THD and THD 2-SO(2) enantiomers was also studied. Degradation of the THD enantiomers was observed under UV light (254 and 366 nm) while THD 2-SO(2) enantiomers were stable at these wavelengths and also when exposed to visible light.
Asunto(s)
Tioridazina/análogos & derivados , Tioridazina/sangre , Tioridazina/química , Antipsicóticos/sangre , Antipsicóticos/química , Humanos , Concentración de Iones de Hidrógeno , Cinética , Modelos Moleculares , Conformación Molecular , Soluciones , EstereoisomerismoRESUMEN
BACKGROUND: Approximately 7% of Caucasians have genetically impaired activity of the cytochrome P450 enzyme CYP2D6 and are classified as poor metabolizers (PM). The disposition of thioridazine has been related to the CYP2D6 phenotype. The present study aimed to evaluate the influence of CYP2D6 and CYP2C9 genotypes, and tobacco smoking on steady-state thioridazine plasma levels. METHODS: Seventy-six Caucasian psychiatric patients receiving thioridazine monotherapy were studied. Debrisoquine metabolic ratio (MR) and steady-state plasma levels of thioridazine and its metabolites, mesoridazine and sulforidazine, as well as CYP2D6 (in 74 patients) and CYP2C9 (in 63 patients) genotypes were determined. RESULTS: The median dose-corrected, steady-state plasma concentrations (C/D) of thioridazine were related to the number of functional CYP2D6 alleles ( P<0.01), being 15.2, 7.2, 4.0, 4.2 nmol/l per milligram in subjects with no, one, two, and three or more functional CYP2D6 genes, respectively. No significant differences were found in the C/Ds of mesoridazine or sulforidazine. No relationship was found between CYP2C9 genotype and plasma levels of thioridazine or its metabolites. The median C/D of thioridazine was significantly ( P<0.001) lower in smokers (4.0 nmol/l per milligram, range: 1.0-15.5; n=58) than in nonsmokers (7.4 nmol/l per milligram, range: 2.8-23.6; n=18). Also, the C/Ds of mesoridazine and sulforidazine were lower in smokers ( P<0.01). The plasma thioridazine/mesoridazine ratio significantly correlated with the debrisoquine MR ( r(2)=0.30, P<0.001). CONCLUSION: The results show that the plasma concentrations of thioridazine and its metabolites are influenced by tobacco smoking and the CYP2D6 genotype, and support the dose-dependent inhibition of CYP2D6 by thioridazine. CYP2C9 does not play an important role in thioridazine metabolism.
Asunto(s)
Antipsicóticos/sangre , Hidrocarburo de Aril Hidroxilasas/genética , Citocromo P-450 CYP2D6/genética , Fumar/metabolismo , Tioridazina/sangre , Adulto , Anciano , Anciano de 80 o más Años , Antipsicóticos/metabolismo , Antipsicóticos/uso terapéutico , Hidrocarburo de Aril Hidroxilasas/metabolismo , Citocromo P-450 CYP2C9 , Citocromo P-450 CYP2D6/metabolismo , Inhibidores del Citocromo P-450 CYP2D6 , Debrisoquina/metabolismo , Femenino , Genotipo , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Trastornos Psicóticos/tratamiento farmacológico , Trastornos Psicóticos/metabolismo , Tioridazina/metabolismo , Tioridazina/uso terapéuticoRESUMEN
Thioridazine cardiotoxicity has been associated with a prolonged heart-rate corrected QT (QTc) interval. However, no systematic studies have been performed on patients at therapeutic doses. The present study aimed to evaluate the influence of dose and plasma concentration of thioridazine and CYP2D6 enzyme status on the QTc interval in psychiatric patients. Sixty-five Spanish European psychiatric patients receiving thioridazine antipsychotic monotherapy were studied. The plasma levels of thioridazine and its metabolites were determined by high-performance liquid chromatography. All patients were phenotyped for CYP2D6 activity with debrisoquine during treatment. Thirty-five patients (54%) had a QTc interval over 420 ms. The lengthening of QTc interval was correlated with plasma concentration (p < 0.05) and daily dose (p < 0.05) of thioridazine. CYP2D6 enzyme hydroxylation capacity, evaluated by debrisoquine metabolic ratio (MR) (p < 0.05) and thioridazine/mesoridazine ratio (p < 0.05), was also correlated with QTc intervals. The present study shows the relationship between QTc interval lengthening among psychiatric patients treated at therapeutical doses with the dose and the plasma concentration of thioridazine. Since debrisoquine MR has been shown to be correlated with the QTc intervals, CYP2D6 enzyme hydroxylation capacity might be relevant in determining the risk for QTc interval lengthening. Patients with impaired CYP2D6 enzyme activity due to enzyme inhibition by thioridazine might be more prone to increased risk of sudden death due to torsade de pointes type cardiac dysrhythmia.
Asunto(s)
Antipsicóticos/efectos adversos , Citocromo P-450 CYP2D6/metabolismo , Síndrome de QT Prolongado/inducido químicamente , Tioridazina/efectos adversos , Adrenérgicos , Adulto , Anciano , Anciano de 80 o más Años , Antipsicóticos/sangre , Antipsicóticos/farmacocinética , Biotransformación , Citocromo P-450 CYP2D6/genética , Debrisoquina , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Hidroxilación , Masculino , Persona de Mediana Edad , Fenotipo , Tioridazina/sangre , Tioridazina/farmacocinéticaRESUMEN
The aim of the present study was to investigate the effect of the distribution interaction between thioridazine and fluoxetine in vivo. Experiments were carried out on male Wistar rats. Animals received thioridazine and fluoxetine separately or jointly, at a dose of 10 mg/kg ip. Concentrations of thioridazine and its metabolites and fluoxetine in the plasma and tissues were measured at 1 h after administration of the drugs (HPLC). Effects of distribution interactions were estimated on the basis of the calculated tissue/plasma and lysosome-poor/lysosome-rich tissue concentration ratios, considering the heart and muscles as lysosome-poor tissues and the lungs, liver and kidneys as lysosome-rich ones. Fluoxetine diminished the tissue/plasma concentration ratio of thioridazine for the lungs, but elevated this ratio for the muscles and heart. On the other hand, thioridazine elevated the brain/plasma and heart/plasma concentration ratios of fluoxetine. Consequently, the thioridazine lysosome-poor/lysosome-rich tissue concentration ratios significantly increased in the presence of fluoxetine. At the same time, thioridazine raised (or showed such a tendency) the heart/lysosome-rich tissue concentration ratios of fluoxetine, not changing significantly the muscles/lysosome-rich tissue concentration ratios of the antidepressant. The presented results provide evidence that the distribution interactions between thioridazine and fluoxetine observed in vitro occur also in vivo, leading to a shift of the drugs from organs rich in lysosomes to those poor in these organella, in particular to the heart. Thioridazine and fluoxetine mutually increased their heart/plasma and heart/lysosome-rich tissue concentration ratios, i.e. the heart/lung, heart/liver and heart/kidneys ratios. Similar results were obtained with lysosome-poor muscles in the case of thioridazine. The obtained results confirm that, apart from the lysosome density in the investigated tissues, the potential metabolic interactions in the liver and the pattern of drug circulation in a body have an important impact on the calculated drug concentration ratios. Moreover, considering serious side-effects of thioridazine (cardiotoxicity, anticholinergic activity), the administration of thioridazine-fluoxetine combination studied herein should be approached with caution, considering appropriate dose adjustment.
Asunto(s)
Fluoxetina/metabolismo , Tioridazina/metabolismo , Animales , Interacciones Farmacológicas/fisiología , Fluoxetina/sangre , Masculino , Ratas , Ratas Wistar , Tioridazina/sangre , Distribución Tisular/fisiologíaRESUMEN
This study aimed to characterize the relationships between administered dosages of psychotropic drugs, plasma drug concentration, and prolactin levels in a group of elderly nursing home residents. In a randomized, placebo-controlled, double-blind crossover design study, blood samples were drawn from 47 nursing home residents at least 6 hours after taking either haloperidol, thioridazine, or lorazepam. Correlations between drug dosage and plasma drug levels were significant for haloperidol and thioridazine, but not for lorazepam. Plasma drug levels were below the levels of detection for most of those taking haloperidol. Lorazepam was detected in the blood of 4 of the participants even after 3 weeks of downward titration to placebo and 6 weeks of placebo. Prolactin level was related to administered dosage only in those who were taking haloperidol. For those taking haloperidol or thioridazine, prolactin levels decreased when participants were on placebo. When an older person is taken off lorazepam, the possibility of residual drug in their bodies even 6 weeks after termination of drug use should be considered. Haloperidol may be clinically active in the brain despite no currently detectable plasma drug concentration.
Asunto(s)
Haloperidol/sangre , Lorazepam/sangre , Prolactina/sangre , Tioridazina/sangre , Tranquilizantes/administración & dosificación , Tranquilizantes/sangre , Anciano , Anciano de 80 o más Años , Ansiolíticos/administración & dosificación , Ansiolíticos/sangre , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Femenino , Haloperidol/administración & dosificación , Humanos , Lorazepam/administración & dosificación , Masculino , Casas de Salud , Placebos , Tioridazina/administración & dosificaciónRESUMEN
1. Because of serious side-effects of thioridazine and tricyclic antidepressants (cardiotoxicity), a possible influence of imipramine and amitriptyline on the pharmacokinetics and metabolism of thioridazine was investigated in a steady state (2-week treatment) in rats. 2. Imipramine and amitriptyline (5 and 10 mg kg(-1) i.p., respectively) elevated 30 and 20 fold, respectively, the concentration of thioridazine (10 mg kg(-1) i.p.) and its metabolites (N-desmethylthioridazine, 2-sulphoxide, 2-sulphone, 5-sulphoxide) in blood plasma. Similar, yet weaker increases in the thioridazine concentration were found in the brain. Moreover, an elevation of thioridazine/metabolite ratios was observed. 3. Imipramine and amitriptyline added to control liver microsomes in vitro inhibited the metabolism of thioridazine via N-demethylation (an increase in K(m)), mono-2-sulphoxidation (an increase in K(m) and a decrease in V(max)) and 5-sulphoxidation (mainly a decrease in V(max)). Amitriptyline was a more potent inhibitor than imipramine of the thioridazine metabolism. 4. The varying concentration ratios of antidepressant/thioridazine in vivo appear to be more important to the final result of the pharmacokinetic interactions than are relative direct inhibitory effects of the antidepressants on thioridazine metabolism observed in vitro. 5. Besides direct inhibition of the thioridazine metabolism, the decreased activity of cytochrome P-450 towards 5-sulphoxidation, produced by chronic joint administration of thioridazine and the antidepressants, seems to be relevant to the observed in vivo interaction. 6. The obtained results may also point to inhibition of another, not yet investigated, metabolic pathway of thioridazine, which may be inferred from the simultaneous elevation of concentrations of both thioridazine and the measured metabolites.
Asunto(s)
Amitriptilina/farmacología , Antidepresivos Tricíclicos/farmacología , Imipramina/farmacología , Tioridazina/farmacocinética , Animales , Antidepresivos Tricíclicos/administración & dosificación , Sistema Enzimático del Citocromo P-450/metabolismo , Citocromos b5/metabolismo , Antagonistas de Dopamina/sangre , Antagonistas de Dopamina/metabolismo , Antagonistas de Dopamina/farmacocinética , Interacciones Farmacológicas , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/metabolismo , Ratas , Ratas Wistar , Tioridazina/sangre , Tioridazina/metabolismoRESUMEN
Thioridazine is metabolized in humans by CYP2D6 to mesoridazine, which is an active metabolite. Two or more CYP2D6 substrates are seldom given simultaneously to elderly patients because potentially dangerous metabolic interactions may occur. It may be valuable to know the CYP2D6 metabolic capacity of such patients to avoid drug interactions, which depend on the metabolic phenotype. The goal of this study was to evaluate the use of the mesoridazine/thioridazine ratio for the estimation of CYP2D6 enzyme capacity. A sensitive and reliable method has been developed for the determination of thioridazine and its metabolites, mesoridazine and sulforidazine. Commonly used central nervous system (CNS) comedications do not interfere with the method. A group of 27 chronic patients with mental illness receiving monotherapy with thioridazine were studied. There were 23 men and 4 women between 37 and 80 years old (mean +/- SD: 61.2 +/- 10.2). The thioridazine/mesoridazine ratio correlated with the debrisoquine metabolic ratio (r = 0.74, p < 0.001). Therefore, the authors suggest that the measurement of thioridazine and its metabolite might be a useful tool to assess CYP2D6 activity during treatment.